ADAM12 promotes clear cell renal cell carcinoma progression and triggers EMT via EGFR/ERK signaling pathway

Table 1 Correlation between ADAM12 expression and clinicopathological characters of patients with clear cell renal cell carcinoma (TCGA)

Clinico- pathological variables	No. of cases	ADAM12 expression		χ²	p value
Clinico- pathological variables	No. of cases	Low	High	χ²	p value
All cases	535	267	268
Gender	Male	157	192	9.723	0.0018**
Gender	Female	110	76
Age	\(<\) 60	109	139	6.557	0.0104*
Age	\(\ge\) 60	158	129
Pathologic T	T1	147	128	9.143	0.0274*
	T2	39	31
	T3	79	100
	T4	2	9
Pathologic N	N0	124	116	9.297	0.0096**
	N1	2	14
	NX	141	138
Pathologic M	M0	209	215	14.24	0.0008***
	M1	32	46
	MX	25	6
TNM stage	I	144	125	4.695	0.1955
	II	32	26
	III	56	67
	IV	35	47
Survival	\(<\) 5	181	200	3.612	0.0574
Survival	\(\ge\) 5	85	65

^*P < .05
^**P < .01
^***P < .001 was considered significant (Chi-square test or Fisher’s exact test)

ISSN: 1479-5876